AnalystsManeka MirchandaneyManeka Mirchandaney's Stock Forecasts
AnalystsManeka Mirchandaney
Sectors:
Industries:
Analyst Ranking
Bottom 11%
#4799 out of 5331 analysts
Average Return
-10.95%
Win Rate
46%6 out of 13
Risk vs Reward
Poor
Good
Maneka Mirchandaney's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Crinetics Pharmaceuticals IncCRNX | +128.18% | $36.77 | $83.90 | 2026-05-15 - 2026-07-21 | Buy |
Crinetics Pharmaceuticals IncCRNX | +93.25% | $26.08 | $50.40 | 2023-09-11 - 2024-09-10 | Buy |
Seagen IncSGEN | +42.15% | $160.91 | $228.74 | 2023-02-16 - 2023-12-13 | Buy |
Viridian Therapeutics IncVRDN | +23.44% | $16.00 | $19.75 | 2021-10-12 - 2022-10-11 | Buy |
Viridian Therapeutics IncVRDN | +14.03% | $16.82 | $19.18 | 2026-05-15 - 2026-07-21 | Buy |
Maneka Mirchandaney Analyst Color
Get additional color on Maneka Mirchandaney's coverage of popular stocks
Maneka Mirchandaney's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Viridian Therapeutics IncVRDN | 3 | Buy | $26.00 | +35.56% | Maintains | 2 months ago |
Crinetics Pharmaceuticals IncCRNX | 3 | Buy | $88.00 | +4.89% | Maintains | 2 months ago |
Incyte CorpINCY | 2 | Hold | $110.00 | -6.30% | Maintains | 5 months ago |
Mink Therapeutics IncINKT | 2 | Buy | $3.00 | N/A | Maintains | 3 years ago |
Seagen IncSGEN | 2 | Buy | $175.00 | N/A | Upgrades | 3 years ago |
Neuphoria Therapeutics IncNEUP | 1 | Buy | $17.00 | N/A | Initiates Coverage On | 5 years ago |
Werewolf Therapeutics IncHOWL | 1 | Buy | $23.00 | N/A | Initiates Coverage On | 5 years ago |
Finch Therapeutics Group IncFNCH | 1 | Buy | $1,020.00 | N/A | Initiates Coverage On | 5 years ago |
Global Blood Therapeutics IncGBT | 1 | Buy | $102.00 | N/A | Initiates Coverage On | 6 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.